IDEXX Laboratories Non-GAAP EPS of $1.83 beats by $0.11, revenue of $801M beats by $19.17M; issues full year guidance
IDEXX Laboratories press release
(NASDAQ:IDXX): Q4 Non-GAAP EPS of $1.83  beats by $0.11.
Revenue of $801M (+11.1% Y/Y)  beats by $19.17M.
Provides initial outlook for 2022 revenue of $3,500 million - $3,565 million vs. consensus of $3.54B, reflecting reported growth of 9% - 11% and organic growth of 10% - 12%.
Estimates 2022 EPS of $9.27 - $9.59 vs. consensus of $9.39, an increase of 8% - 11% as reported and 12% - 16% on a comparable basis, including an estimated $0.15 per share or ~2% EPS growth impact from higher projected international tax rates